PeptideDDP
Global Peptide Logistics
Industry notes on peptide logistics, cold chain, compliance and B2B supply-chain practice.
Ascletis will present preclinical ASC48 and ASC37 posters at ObesityWeek 2026, including a company-attributed claim of a 6-fold longer half-life than retatrutide in NHP.
Read article →Forbes Health's 2026 ranking of online tirzepatide programs highlights price transparency and regulatory scrutiny, with implications for peptide therapy clinics and telehealth platforms.
Read article →Hanmi's Eppe launched in Korea at 129,800 won for four weeks, undercutting Wegovy and Mounjaro on price but facing unproven comparative efficacy and a possible managed-coverage shift.
Read article →A Springer Medicine page titled on GIPR and GLP-1R agonism behavioral research carries no study results, only search instructions and CME promotions — a citation risk for peptide…
Read article →Novo Nordisk will unveil real-world PLATINUM-Truveta data comparing semaglutide 2.4 mg with resmetirom in MASH at AASLD 2025, with results still undisclosed.
Read article →Post hoc ATTAIN-1 and ATTAIN-2 analyses presented at AHA 2026 show oral orforglipron lowered office systolic BP versus placebo over 72 weeks, partly beyond weight loss.
Read article →Five state Medicaid programs that dropped GLP-1 obesity coverage saw reimbursed dispensing fall 84.7% versus continuing states, with minimal substitution to older weight-loss drugs.
Read article →Ascletis' oral GLP-1 ASC30 met its Phase II type 2 diabetes primary endpoint with 1.6%–1.7% placebo-adjusted HbA1c reductions, while Phase III obesity trials continue.
Read article →Forbes Health's GLP-1 cost explainer sets 2026 benchmarks: Wegovy self-pay from $149, compounded versions at $100–$300 monthly, and a $50 Medicare Part D program.
Read article →A post hoc phase 2 analysis presented at The Liver Meeting 2026 reports survodutide improved MASH and fibrosis endpoints across all weight-loss categories, including patients losing under 5%.
Read article →